AMAG Pharmaceuticals, Inc. Release: Study Shows Mugard® Is More Effective Than Sham-Control At Reducing Mouth And Throat Soreness Associated With Oral Mucositis In Head And Neck Cancer Patients

WALTHAM, Mass., Feb. 18, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the publication of data from a multi-institutional trial of MuGard in the online edition of the journal Cancer available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full. MuGard is a mucoadhesive hydrogel. The randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing pain associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.

Help employers find you! Check out all the jobs and post your resume.